Title: The ameliorative role of Camellia sinensis extract against spleenʼs extra-medullary hematopoiesis in acute myeloproliferative disorder model in rats: Histopathological study

Abstract

Leukemia represents a kind of malignancy that affects the bone marrow and blood, resulting in un-controlled proliferation of abnormal leucocytes. Cyclophosphamide (CP) chemotherapy has a number of side effects, including liver toxicity and renal toxicity. The purpose of the current study was to look into the therapeutic role of Camellia sinensis extract (CSE) on caused leukemia in adult male albino rats. Following induction of leukemia with benzene injection, both healthy and leukemic rats were separated into four groups of ten rats each: 1) untreated control rats, 2) induced-leukemia rats, 3) leukemia rats treated orally with (350 mg/kg) daily CSE for 4 weeks, and 4) leukemia rats treated with CP (7.5 mg/kg/48 hr.) for 4 weeks by intraperitoneal injection. At the conclusion of the experiment, the rats were slaughtered. Hematological markers were assessed, including the total blood count. The results showed that treating leukemic rats with CSE effectively alleviated the leukemic complication signs, as evidenced by a significant reduction in WBCs count; additionally, CSE significantly ameliorated histopathological alterations in the spleen, restoring normal area percent of collagen fibers, PAS-stained general carbohydrates, and Myeloperoxidase-positive stained splenocytes in a benzene-induced leukemia model. It is possible to conclude that CSE has anti-leukemic potential, making it a promising treatment option for leukemia.